
Histone Deacetylase Inhibitors Market by Class (Class I HDACs, Class II HDACs, Class III HDACs), Application (Central Nervous System Disorders, Neurology, Oncology) - Global Forecast 2024-2030
Description
Histone Deacetylase Inhibitors Market by Class (Class I HDACs, Class II HDACs, Class III HDACs), Application (Central Nervous System Disorders, Neurology, Oncology) - Global Forecast 2024-2030
The Histone Deacetylase Inhibitors Market size was estimated at USD 16.43 billion in 2023 and expected to reach USD 18.32 billion in 2024, at a CAGR 11.96% to reach USD 36.25 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Histone Deacetylase Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Histone Deacetylase Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Histone Deacetylase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bristol Myers Squibb Company, Celleron Therapeutics Ltd., Eisai Co., Ltd., Karyopharm Therapeutics Inc., MEI Pharma Inc., Merck KGaA, Midatech Pharma PLC, Novartis AG, Oncolys BioPharma Inc., Regenacy Pharmaceuticals, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Spectrum Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., and Tokyo Chemical Industry Co. , Ltd..
Market Segmentation & Coverage
This research report categorizes the Histone Deacetylase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:
Class
Class I HDACs
Class II HDACs
Class III HDACs
Application
Central Nervous System Disorders
Neurology
Oncology
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Histone Deacetylase Inhibitors Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Histone Deacetylase Inhibitors Market?
3. What are the technology trends and regulatory frameworks in the Histone Deacetylase Inhibitors Market?
4. What is the market share of the leading vendors in the Histone Deacetylase Inhibitors Market?
5. Which modes and strategic moves are suitable for entering the Histone Deacetylase Inhibitors Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Histone Deacetylase Inhibitors Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing incidence of cancer coupled with need for effective treatment therapies
- 5.1.1.2. Increasing application in prognosis, treatment and diagnosis of chronic diseases
- 5.1.1.3. Rising need from psychiatry and neurology attributed to their mood stabilizing and anti-epileptic properties
- 5.1.2. Restraints
- 5.1.2.1. Dearth of awareness among people and lack of reimbursement policies
- 5.1.2.2. High cost of raw material and lack of trained professionals
- 5.1.3. Opportunities
- 5.1.3.1. Rising adoption of advanced technologies and collaboration among manufacturers and companies
- 5.1.3.2. Increasing investment for drug development from government and private organizations
- 5.1.4. Challenges
- 5.1.4.1. Strict mandates for the production and probable side effects such as toxicity
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Histone Deacetylase Inhibitors Market, by Class
- 6.1. Introduction
- 6.2. Class I HDACs
- 6.3. Class II HDACs
- 6.4. Class III HDACs
- 7. Histone Deacetylase Inhibitors Market, by Application
- 7.1. Introduction
- 7.2. Central Nervous System Disorders
- 7.3. Neurology
- 7.4. Oncology
- 8. Americas Histone Deacetylase Inhibitors Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Histone Deacetylase Inhibitors Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
- 10. Europe, Middle East & Africa Histone Deacetylase Inhibitors Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. AstraZeneca PLC
- 12.1.2. Bristol Myers Squibb Company
- 12.1.3. Celleron Therapeutics Ltd.
- 12.1.4. Eisai Co., Ltd.
- 12.1.5. Karyopharm Therapeutics Inc.
- 12.1.6. MEI Pharma Inc.
- 12.1.7. Merck KGaA
- 12.1.8. Midatech Pharma PLC
- 12.1.9. Novartis AG
- 12.1.10. Oncolys BioPharma Inc.
- 12.1.11. Regenacy Pharmaceuticals, Inc.
- 12.1.12. Shenzhen Chipscreen Biosciences Co., Ltd.
- 12.1.13. Spectrum Pharmaceuticals, Inc.
- 12.1.14. Syndax Pharmaceuticals, Inc.
- 12.1.15. Tokyo Chemical Industry Co. , Ltd.
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. HISTONE DEACETYLASE INHIBITORS MARKET RESEARCH PROCESS
- FIGURE 2. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2023 VS 2030
- FIGURE 3. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HISTONE DEACETYLASE INHIBITORS MARKET DYNAMICS
- FIGURE 7. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
- FIGURE 8. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 10. HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.